Borrowing from the body, with peptidesfoundation
The body supplied the starting material. Peptide chemistry changed its staying power. I’m tracing the consequences of making a familiar signal last.
A longer life for GLP-1
The gut already makes GLP-1, a hormone involved in appetite and blood-sugar control. Its life in circulation is about 2 minutes. Semaglutide borrows that hormone’s activity and, through chemical alterations, lasts roughly a week. The review of semaglutide’s pharmacology and safety brings the cleverness and the discomfort into the same account: a useful medicine can also bring nausea and an increased risk of gallbladder disease.
Duration used to seem like a convenience to me. Here it is a substantial part of the invention. One alteration helps the peptide resist an enzyme that would break it down; another gives it an attachment to albumin, a plentiful protein in blood. The starting material came from human biology. The persistence was engineered.
That is the foundation that interests me: the body’s existing signals, and the consequences of borrowing them for medicine. “Natural” seems an oddly incomplete compliment for work this deliberate.
The biological starting materials
Tesamorelin’s starting material is GHRH, the hormone that prompts the pituitary to release growth hormone. Protecting one end of that peptide lets the signal persist longer. The fat changes come further down the chain of events.
Thymosin alpha-1 offers a different kind of borrowing. Thymalfasin reproduces the sequence of a thymic peptide instead of substantially redesigning it. The identical sequence initially suggested an easier medical story to me. A complicated illness soon upsets that expectation: the biological original and a successful intervention are separate questions.
PT-141, or bremelanotide, takes its chemical starting point from alpha-MSH, a melanocortin hormone. Its central action in sexual-desire research leads into the brain. This family of signals reaches well beyond a single function.
The consequences of staying
The STEP 1 trial gives semaglutide’s chemistry a human consequence: adults with overweight or obesity without diabetes had a mean body-weight change of −14.9% at 68 weeks, against −2.4% with placebo. My admiration for STEP 1 begins with the observed weight change. The digestive tract also belongs in the account, because adverse effects occur in people with lives to get on with.
There is a similar complication in the melanocortin story. The bremelanotide prescribing information describes transient blood-pressure increases and pigmentation changes alongside its narrow approved use. A hormone’s biological ancestry offers no automatic reassurance about extending or redirecting its activity.
Explore the collection
Semaglutide follows the alterations that give a gut hormone more staying power, then the results of the large trials. Tesamorelin starts at the protected end of GHRH and follows the pituitary’s response.
Thymosin alpha-1 begins with the thymic peptide and its synthetic counterpart, thymalfasin. PT-141 follows a melanocortin signal through desire, brain imaging and a hamster experiment that complicates the reward story.
The comparison puts those biological starting materials together. The questions deal with hypothalamic peptides and names that are easily mixed up.